Aclaris Therapeutics, Inc.
(NASDAQ : ACRS)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 0.70%71.725.6%$211.67m
CTLTCatalent, Inc. 2.13%95.462.1%$143.63m
VRXValeant Pharmaceuticals International, Inc. 3.46%19.9114.1%$117.15m
JAZZJazz Pharmaceuticals Plc -0.19%150.712.4%$77.32m
BHCBausch Health Cos., Inc. 3.46%19.910.0%$68.52m
SAGESAGE Therapeutics, Inc. 2.71%71.758.6%$66.16m
PRGOPerrigo Co. Plc 3.23%49.896.8%$54.78m
GWPHGW Pharmaceuticals Plc 0.77%137.496.1%$52.28m
ARGXargenx SE 0.79%289.020.0%$47.90m
UTHRUnited Therapeutics Corp. 2.72%133.4714.1%$46.42m
AMRNAmarin Corp. Plc 1.62%5.011.5%$42.21m
ICLRICON plc 0.59%200.504.2%$39.26m
CORTCorcept Therapeutics, Inc. 0.81%23.555.4%$32.46m
ICPTIntercept Pharmaceuticals, Inc. 0.57%35.4016.8%$30.56m
PCRXPacira Biosciences, Inc. -2.29%60.6110.0%$30.15m

Company Profile

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.